Macrophage Induction of T-Suppressor Cells in Pesticide-Exposed and Protozoan-Infected Mice

by Leland D. Loose*

The use of infectious pathogens has allowed the detection of the development of synergism between pathogens and ubiquitous environmental chemical contaminants. This synergism has been demonstrated to result in a state of immunosuppression which either did not occur in the independent and singular presence of the chemical or pathogen and/or was greater than additive when both were combined. The immunosuppression was distinct with regard to the organochloride used and, therefore, is not a ubiquitous characteristic of all organochlorides. The production of a macrophage soluble factor which appeared to induce T-suppressor cells was demonstrated in hepatic Kupffer cells from mice administered 5 ppm of dieldrin for 10 weeks and then infected with *Leishmania tropica* promastigotes. The factor was not generated in mice administered dieldrin and infected with malaria nor in mice administered only dieldrin nor in mice only infected with *Leishmania*. Additional studies revealed a profound impairment in macrophage antigen processing with macrophages obtained from mice administered dieldrin. The use of pathogen models may allow the immunosuppressive potential of environmental chemical contaminants to be expressed in a more sensitive manner.

Introduction

Previous studies have demonstrated that environmental chemical contaminants impair host defense responses to a malaria challenge and to gram-negative endotoxin (1). In conjunction with these alterations, a significant reduction in antibody formation to sheep erythrocytes, (SRBC), a T-dependent and macrophage-processed antigen, was observed (2). These functional alterations were demonstrated in the absence of any lymphoid histopathologic changes. Further studies to examine cell-mediated immunity (CMI) in the xenobiotic treated mice revealed an essentially normal CMI responsiveness as measured by the graft-versus-host assay, mixed lymphocyte culture reaction, polyclonal mitogen activity and lymphocytotoxicity response (3). Since it was felt that the CMI parameters which were measured and which were unaltered were, in general, macrophage-independent whereas the response to malaria, endotoxin and SRBC were macrophage-dependent, the cellular lesion responsible for the impaired malaria, endotoxin and SRBC responses could reside at the level of the macrophage.

Measurements of macrophage effector activity, i.e., cellular respiration, phagocytic activity, phagocytic capacity and chemotaxis revealed no alteration in these parameters (4). However, macrophage effector activity, i.e., antigen processing and tumor cell killing were significantly impaired (5). Therefore, it was speculated that if the cellular lesion responsible for the xenobiotic-induced immunosuppression was at the level of the macrophage, that the lesion could be due to: a functional impairment in the macrophage, induction of a population of suppressor macrophages, production of suppressor...
Animals

Male BALB/c mice (18-20 g) were used throughout all studies.

Chemicals

Dieldrin (Shell) and hexachlorobenzene (HCB, Eastman) were administered in the diet at 1 and 5 ppm and 5 and 100 ppm, respectively. Control mice received untreated powdered Wayne Lab Blox. Food and water were provided ad libitum, and a 12:12 day:night photoperiod was maintained. Dietary administration of the test chemicals was for 3, 5 or 10 week periods.

Parasites

Plasmodium berghei (NYU-2) was passaged weekly by intraperitoneal (IP) injection of $1 \times 10^6$ infected erythrocytes. The survival time of infected mice injected with this strain of murine malaria at the stated inoculum was approximately 10-12 days. Leishmania tropica was initially derived from a biphasic blood agar medium and then adapted to a defined culture medium consisting of MEM 199 with 10% heat inactivated fetal calf serum. Subcultures were made weekly. The parasite stage used was a promastigote in a mid- to late-log phase. Survival time of BALB/c mice injected intradermally (ID) with $1 \times 10^6$ promastigotes was approximately 15-20 weeks.

Antibody Formation

Antibody production was assessed using the direct Jerne and Nordin (6) plaque assay as previously described (2). Plaque formation to polyvinylpyrrolidone (PVP, Sigma), a T-independent antigen, utilized passively sensitized SRBC coated with PVP by the method of Boyden (7). Preliminary studies revealed that the kinetics of splenic plaque formation in experimental and control mice were comparable and, therefore, only day 4 was used to subsequently enumerate plaques.

Mononuclear Spleen Cell Populations

Splenic T- and B-lymphocytes were enumerated as previously described (8). T-cells were detected by the presence of theta antigen (Thy-1) and subsequent cytotoxicity induced by anti-theta serum. B-cells were detected by the presence of surface immunoglobulin (Ig) using fluorescein-tagged, goat anti-mouse Ig. Splenic macrophages were stained by the method of Yam, Li and Crosby (9), which detects the presence of surface neutral esterase, a cytochemical marker for macrophages.

Lymphocyte Blastogenesis

Spleens were removed aseptically from mice, controls and experimentals, at the stated intervals (see Tables 5-8), and teased apart in cold RPMI 1640 and strained through a 10xx silk cloth. This single cell suspension was then passaged through nylon wool (Leuko-Pak leukocyte filter, Fenwal Labs, Deerfield, Ill.) which was soaked in saline for 2 hr at 37°C then rinsed three times in doubly distilled water for 3 days, autoclaved and then dried. A 60-ml disposable syringe barrel was then packed with 6 g of nylon wool and then washed with 20 ml of RPMI 1640 containing 5% fetal calf serum. The columns were then drained and placed in a 37°C incubator for 1 hr prior to being loaded with $10^6$ spleen cells in 20 ml of RPMI 1640. The column, with the cells, was incubated at 37°C for 45 min prior to eluting the cells at a 1 ml/min rate. The T-cell enriched suspension was then concentrated by centrifugation at 250 g for 15 min. Cell viability, as determined by trypan blue dye exclusion, was > 85%, and > 95% of the cells were theta positive. The enriched T-cell population was then dispensed in 200 μl volumes containing $4 \times 10^5$ cells into Linbro flat-bottomed microtest plates (Flow Lab). The RPMI 1640 medium was supplemented with 2mM L-glutamine, 10% fetal calf serum, 50-100 units of penicillin and 50-100 μg of streptomycin/ml. In addition, phytohemagglutinin (PHA-M, B grade, Difco) was added at a concentration of 0.1 μg/well. The plates were incubated at 37°C in humidified 5% CO₂ for 48 hr, after which 0.1 μCi of $^3$H (specific activity 5 Ci/mmole) was added and the plates incubated for an additional 16 hr prior to harvest. Cell harvesting was conducted as previously described (3), and data are presented as cpm $\times 10^3$. Anti-theta serum treatment of the nylon wool enriched T-cell preparation utilized a 1:80 dilution of anti-Thy-1 antiserum (Cedarlane Labs) and a 1:10 dilution of...
Low-Tox rabbit complement incubated together for 30 min at 37°C. Mitomycin C treatment consisted of incubating the nylon wool passaged cells (10⁴/ml) with 20 μg of mitomycin C (Sigma) for 25 min at 37°C. The cells were washed three times in RPMI 1640 prior to use in blastogenesis studies (3).

Macrophage Assay

Alveolar, splenic and peritoneal macrophages were isolated as previously described (4). Briefly, alveolar macrophages were isolated by lavage of the lung with saline, peritoneal macrophages were isolated by saline lavage of the peritoneal cavity, and splenic macrophages were isolated by surface adsorption. Hepatic Kupffer cells were isolated by partial enzymatic digestion of the liver as described by Stege et al. (10). The macrophage preparations were incubated overnight in RPMI 1640 plus 10% FCS in a 5% CO₂:humidified atmosphere at a cell concentration of 1 × 10⁷ cells/culture plate. The following day the cell supernatant was decanted off and centrifuged at 250 g for 20 min to remove cell debris. A 50 μl aliquot of this supernatant was then added to the T-cell blastogenesis cultures, replacing 50 μl of the RPMI 1640 medium. PHA-induced blastogenesis studies were then conducted as described above.

Macrophage antigen processing of SRBC, a T-dependent antigen which requires macrophage cooperation for immunogenicity, was conducted as previously described (5).

Statistics

All data are reported as the mean with significance denoted by an asterisk where p < 0.05. Significance was determined by using the Student’s t test. Significance for mortality data was calculated using the time-effect evaluation of Litchfield (11).

Results

As can be seen in Table 1, the addition of either 1 or 5 ppm of dieldrin to the diet of mice exacerbated the lethality induced by a challenge infection with either the malaria parasite Plasmodium berghei (NYU-2) or Leishmania tropica. The lethality synergized by dieldrin and the parasites appeared to be both time and dose related. However, mice administered 5 or 100 ppm of HCB and then challenged with malaria or Leishmania expressed a synergy only with Leishmania and not malaria. The mortality induced by Leishmania was more marked in dieldrin-exposed mice than in HCB-exposed mice.

When the dieldrin and HCB-treated mice which were infected with malaria or Leishmania and then evaluated for their ability to produce antibody to SRBC, a suppressive synergism was noted primarily in HCB-treated mice (Table 2). In these mice, the splenic plaque forming response was more suppressed in the combination of HCB + infected mice than in those only HCB-treated or only infected. In dieldrin-treated mice, a synergism was observed only in mice which received 5 ppm of dieldrin plus infection with Leishmania.

Although a suppressed SRBC response was noted in HCB-treated mice infected with either malaria or Leishmania, a decreased antibody formation to PVP, a T-independent antigen, was observed only in Leishmania-infected mice exposed to dieldrin or HCB. Malaria did not act synergistically with dieldrin or HCB to elicit an impaired response to PVP (Table 3). The decreased antibody formation to PVP in dieldrin- and HCB-treated mice infected with Leishmania was time- and dose-related in dieldrin-treated mice but was only time-related in HCB-treated mice.

An examination of the number of splenic T-cells, B-cells and macrophages revealed no consistent significant alterations in the cell types in either

Table 1. Mortality in Plasmodium berghei and Leishmania tropica infected mice administered dieldrin or HCB.*

| Weeks | Dieldrin, 1 ppm | Dieldrin, 5 ppm | HCB, 5 ppm | HCB, 100 ppm |
|-------|----------------|----------------|------------|--------------|
|       | Malaria | Leishmania | Malaria | Leishmania | Malaria | Leishmania | Malaria | Leishmania |
| 3     | 10.4    | 123.5       | 10.8     | 80.8*       | 12.0    | 97.6*       | 11.1    | 73.7*       |
| 6     | 10.6    | 81.2*       | 7.2*     | 57.7*       | 11.9    | 83.1*       | 9.8     | 60.0*       |
| 10    | 7.1*    | 53.9*       | 4.7*     | 23.0*       | 10.8    | 75.6*       | 7.0*    | 41.1*       |
| Control | 12.3    | 119.0       |          |             |          |            |          |             |

*Male BALB/c mice (18-20 g) were administered dieldrin or HCB at 1 and 5 or 5 and 100 ppm, respectively, for 3, 6 or 10 weeks and then challenged with either 1 × 10⁶ Plasmodium berghei (NYU-2) infected erythrocytes (IP) or 1 × 10⁶ Leishmania tropica promastigotes injected ID.

**Mean survival time (days) is denoted for experimental and control mice and significance is indicated by an asterisk where p < 0.05; n = 12 per group. Following injection of the parasite(s) all dietary administration of HCB or dieldrin ceased.

February 1982
Table 2. Direct splenic plaque formation to SRBC in mice infected with malaria or Leishmania with administration of dieldrin or HCB.*

| Time, weeks | Chemical treatment | Splenic PFC/10^6 cells |
|-------------|--------------------|-------------------------|
|             | Agent              | Conc. ppm               | No infecting organism | Malaria | Leishmania |
|             |                    |                        |                       |         |            |
| 3           | None               | –                      | 255^b                 | 107^c   | 186^c      |
| 3           | Dieldrin           | 1                      | 240^d                 | 128     | 190        |
| 6           | Dieldrin           | 5                      | 137^d                 | 91      | 76         |
| 6           | Dieldrin           | 5                      | 200^d                 | 117     | 133        |
| 10          | Dieldrin           | 1                      | 91^d                  | 72      | 43         |
| 10          | Dieldrin           | 5                      | 107^d                 | 99      | 101        |
| 10          | HCB                | 5                      | 50^d                  | 38      | 21         |
| 10          | HCB                | 100                    | 280^d                 | 148     | 107        |
| 6           | HCB                | 5                      | 172^d                 | 72      | 58         |
| 6           | HCB                | 100                    | 248^d                 | 109     | 82         |
| 10          | HCB                | 5                      | 103^d                 | 40      | 37         |
| 10          | HCB                | 100                    | 178^d                 | 77      | 49         |
|             |                    |                        | 69^d                  | 19      | 15         |

*Splenic PFC/10^6 cells determined on day 4 following 10 infection of 0.1 ml of 10% SRBC. Malaria-infected mice (1 × 10^6 parasites, IP) were immunized on day 3 post infection, and Leishmania infected mice (1 × 10^6 promastigotes, ID) were immunized 20 days post infection.

Control consisting of untreated but immunized mice.

Control consisting of PFC responses in infected mice receiving no chemical treatment.

Control consisting of chemically treated, on infected mice.

cosidered, infected or chemical-treated plus infected mice as compared to control values (Table 4). The only statistically significant alteration occurred in the 5 ppm dieldrin-treated plus Leishmania-infected mice at the 10 week exposure period in which a significant decrease in macrophages, T-cells and B-cells was observed as compared to normal controls, infected animals, or 5 ppm dieldrin at the 10 week exposure period.

In contrast to the apparent absence of any consistent alteration in T-cell numbers in chemical-treated plus infected mice, a significant depression in HCB and dieldrin-treated plus Leishmania-infected mice to the T-cell mitogen, PHA, was demonstrated (Table 5). Isolated splenic T-cells from Leishmania-infected mice which had been administered dieldrin or HCB had a significantly depressed response to the polyclonal T-cell mitogen PHA. Neither dieldrin or HCB alone or malaria or Leishmania infection alone caused any change in the splenic T-cell enriched population response to PHA. Furthermore, malaria infection in dieldrin or HCB-treated mice

Table 3. Direct splenic plaque formation to PVP in mice infected with malaria or Leishmania with administered dieldrin or HCB.*

| Time, weeks | Chemical treatment | Splenic PFC/10^6 cells |
|-------------|--------------------|-------------------------|
|             | Agent              | Conc. ppm               | No infecting organism | Malaria | Leishmania |
|             |                    |                        |                       |         |            |
| 3           | None               | –                      | 287^b                 | 180^c   | 267^c      |
| 3           | Dieldrin           | 1                      | 205                   | 199     | 133        |
| 6           | Dieldrin           | 5                      | 222                   | 150     | 99         |
| 6           | Dieldrin           | 5                      | 227                   | 93      | 42         |
| 10          | Dieldrin           | 1                      | 173                   | 93      | 42         |
| 10          | Dieldrin           | 5                      | 172                   | 42      | 42         |
| 3           | HCB                | 5                      | 293                   | 174     | 142        |
| 6           | HCB                | 100                    | 214                   | 129     | 142        |
| 10          | HCB                | 5                      | 231                   | 87      | 76         |
| 10          | HCB                | 100                    | 153                   | 76      | 76         |

*PVP (Sigma) was administered IP at a dose of 2.5 μg/mouse to mice infected with P. berghei (1 × 10^5 parasites, IP) on day 4 post-immunization and to mice infected with L. tropica (1 × 10^6 promastigotes, ID) on day 20 post infection.

Untreated, uninfected mice.

Direct plaques were enumerated on day 4 post immunization, n = 12.

Environmental Health Perspectives
Table 4. Mononuclear (T, B, Mϕ) cells in mice infected with malaria or Leishmania and receiving dieldrin or HCB. *

| Time, weeks | Chemical treatment | Concentration (ppm) | Infecting organism | T, % | B, % | Mϕ, % |
|-------------|--------------------|---------------------|--------------------|------|------|------|
| -           | None               | -                   | None               | 30   | 51   | 12   |
| -           | None               | -                   | Malaria            | 34   | 60   | 15   |
| -           | None               | -                   | Leishmania         | 31   | 58   | 13   |
| 3           | Dieldrin           | 1                   | None               | 33   | 54   | 15   |
|             |                    |                     | Malaria            | 33   | 50   | 12   |
|             |                    |                     | Leishmania         | 30   | 50   | 15   |
| 3           | Dieldrin           | 5                   | None               | 20   | 49   | 18   |
|             |                    |                     | Malaria            | 24   | 56   | 10   |
|             |                    |                     | Leishmania         | 32   | 47   | 10   |
| 6           | Dieldrin           | 1                   | None               | 29   | 48   | 12   |
|             |                    |                     | Malaria            | 30   | 52   | 15   |
|             |                    |                     | Leishmania         | 24   | 41   | 12   |
| 6           | Dieldrin           | 5                   | None               | 30   | 42   | 10   |
|             |                    |                     | Malaria            | 27   | 57   | 12   |
|             |                    |                     | Leishmania         | 24   | 40   | 8    |
| 10          | Dieldrin           | 1                   | None               | 37   | 50   | 12   |
|             |                    |                     | Malaria            | 27   | 46   | 9    |
|             |                    |                     | Leishmania         | 23   | 37   | 10   |
| 10          | Dieldrin           | 5                   | None               | 27   | 40   | 14   |
|             |                    |                     | Malaria            | 20   | 60   | 12   |
|             |                    |                     | Leishmania         | 19   | 41   | 5    |
| 3           | HCB                | 5                   | None               | 30   | 49   | 12   |
|             |                    |                     | Malaria            | 32   | 54   | 12   |
|             |                    |                     | Leishmania         | 33   | 50   | 10   |
| 3           | HCB                | 100                 | None               | 27   | 57   | 14   |
|             |                    |                     | Malaria            | 31   | 50   | 15   |
|             |                    |                     | Leishmania         | 30   | 46   | 9    |
| 6           | HCB                | 5                   | None               | 28   | 51   | 15   |
|             |                    |                     | Malaria            | 32   | 51   | 14   |
|             |                    |                     | Leishmania         | 37   | 49   | 11   |
| 6           | HCB                | 100                 | None               | 25   | 54   | 11   |
|             |                    |                     | Malaria            | 31   | 46   | 12   |
|             |                    |                     | Leishmania         | 29   | 40   | 11   |
| 10          | HCB                | 5                   | None               | 34   | 47   | 10   |
|             |                    |                     | Malaria            | 30   | 47   | 16   |
|             |                    |                     | Leishmania         | 28   | 47   | 9    |
| 10          | HCB                | 100                 | None               | 27   | 42   | 13   |
|             |                    |                     | Malaria            | 26   | 40   | 11   |
|             |                    |                     | Leishmania         | 27   | 48   | 9    |

*Mononuclear splenic cells (T-cells, B-cells, and macrophages) as mean percentages; n = 12. Cellular populations were enumerated on day 4 in malaria-infected mice (P. berghei, 1 x 10⁶, IP) and day 20 in Leishmania-infected (1 x 10⁶ promastigotes, ID) mice.

did not alter PHA responsiveness. The dieldrin + Leishmania-induced impairment in PHA activity was time- and dose-related, whereas the change seen in HCB + Leishmania-infected animals was only time-related, i.e., exacerbation with extended dietary administration of HCB.

To further evaluate the impaired PHA responsiveness in dieldrin-treated mice infected with Leishmania, the splenic T-cell enriched population was subjected to mitomycin C and anti-theta (anti-Thy-1) serum. Mitomycin C and anti-theta serum abolished the mitogenic response to PHA, as measured by ³H-thymidine incorporation. When splenic T-cells taken from dieldrin + Leishmania infected mice were added at one-half the normal cell concentration (4 x 10⁶) to normal (control) splenic T-cells a significant inhibition was demonstrated (Tables 6 and 7. This inhibition could be blocked by pretreating the dieldrin + Leishmania-infected mouse derived T-cells with mitomycin C which suggested an active cell-mediated suppressor. Similarly, when the splenic T-cells from the dieldrin + Leishmania-infected mice were pre-treated with anti-Thy-1 antisera their inhibitory or suppressive effect was also abolished. These data suggested the presence of a Thy-1 positive suppressor cell in the spleen of the dieldrin-treated/Leishmania-infected mice.

Since the Leishmania promastigote has been described as a parasite infecting and proliferating in macrophages it was subsequently decided to de-
Table 5. PHA response of splenic T-cell nylon wool-enriched populations from mice infected with malaria or Leishmania and receiving dieldrin or HCB.*

| Time, weeks | Chemical treatment | Agent | Conc, ppm | No infecting organism | PHA response, cpm $\times 10^3$ |
|-------------|--------------------|-------|-----------|----------------------|-------------------------------|
|             |                    |       |           |                      | Malaria | Leishmania |
|             |                    |       |           |                      |       |           |
| 0           |                    |       |           |                      |       |           |
| 3           |                    | Dieldrin | 1         |                      | 39    | 41        | 44        |
| 6           |                    | Dieldrin | 5         |                      | 48    | 43        | 40        |
| 10          |                    | Dieldrin | 1         |                      | 39    | 43        | 40        |
|              |                    | HCB    | 5         |                      | 49    | 47        | 36        |
| 3           |                    | HCB    | 100       |                      | 10    | 37        | 30        |
| 6           |                    | HCB    | 5         |                      | 44    | 37        | 11        |
| 10          |                    | HCB    | 100       |                      | 41    | 39        | 29        |

*Splenic cells were isolated from malaria- and Leishmania-infected mice on days 4 and 20, respectively, post infection and eluted from a washed nylon wool (Fenwal) column (60 ml syringe barrel) with RPMI 1646 with 5% ICS at a rate of 1 ml/min. PHA (Difco) was added at a concentration of 0.1 $\mu$g/well containing 200 $\mu$l of a 2 $\times 10^7$ cell/ml suspension. All plates (Flow, Linbro microtest) were inoculated with PHA for 48 hr with 0.1 $\mu$Ci of $^3$H (5 Ci/mnmole) added 16 hr before harvest.

Table 6. PHA response of mitomycin C-treated splenic T-cell enriched population from Leishmania-infected mice administered dieldrin.*

| Cell origin | PHA response, cpm $\times 10^3$ |
|-------------|--------------------------------|
| Normal      | 43                             |
| Normal + mitomycin C (20 $\mu$g/ml) | 2                             |
| Leishmania (d. 20) | 44                            |
| Leishmania + mitomycin C | 6                             |
| Dieldrin (5 ppm, 10 wk) | 40                            |
| Dieldrin + mitomycin C | 3                             |
| Dieldrin/Leishmania | 10                            |
| Dieldrin/Leishmania + Normal | 15                            |
| Dieldrin/Leishmania (mitomycin C) + Normal | 26                            |
| Half number of normal | 24                             |
| Normal + normal mitomycin C-treated cells | 22                            |

*Cell preparations were used as previously described in Table 5. The enriched T-cell population at a concentration of 1 $\times 10^7$ cells/ml was incubated with 20 $\mu$g/ml of mitomycin C (Sigma) for 25 min at 37°C. The cells were washed three times with fresh medium and numbers adjusted for subsequent use. Each study was conducted in triplicate.

Table 7. PHA response of anti-theta treated splenic T-cell enriched population from Leishmania-infected mice administered dieldrin.*

| Cell origin | PHA response, cpm $\times 10^3$ |
|-------------|--------------------------------|
| Normal      | 49                             |
| Normal + anti-theta | 4                             |
| Leishmania (d. 20) | 43                            |
| Leishmania + anti-theta | 5                             |
| Dieldrin (5 ppm, 10 wk) | 48                            |
| Dieldrin + anti-theta | 2                             |
| Dieldrin/Leishmania | 12                            |
| Dieldrin/Leishmania + Normal | 14                            |
| Dieldrin/Leishmania (anti-theta) + Normal | 30                            |
| Half number of normal | 21                             |
| Normal + normal anti-theta treated cells | 20                            |

*All cells were prepared as described. Nylon-wool passaged spleen cells were incubated with a 1:80 dilution of anti-thy-1 antiserum (Cederlane Labs) and a 1:10 dilution of rabbit complement.

terminie if macrophage dysfunction contributed to the induction of the Thy-1 positive suppressor cells. Hepatic Kupffer cells, alveolar, splenic and peritoneal macrophages isolated from dieldrin treated (5 ppm, 10 wk) Leishmania-infected (day 20) mice were cultured for 24 hr, after which their supernatant, following centrifugation at 250g at 4°C for 15 min, was added to cell cultures simultaneously with PHA. Supernatant from hepatic Kupffer cells, and to a lesser extent from splenic macrophages, but not alveolar or peritoneal macrophages, when added to either control T-cells or T-cells from Leishmania-infected mice did not alter their response to PHA, however, when added to T-cells from dieldrin- or HCB-treated mice or from dieldrin/Leishmania-infected mice, the supernatant suppressed the T-cell response to PHA (Table 8). Supernatant from macrophage populations from dieldrin-treated mice or Leishmania-infected mice did not alter the response to PHA. The suppressive activity was removed from the supernatant when dialyzed against phosphate-buffered saline overnight at 4°C. The production by hepatic Kupffer cells, and to a lesser extent splenic macrophages, of a suppressive
Table 8. Macrophage induced alteration of PHA response of splenic T-cell enriched population from Leishmania-infected mice administered dieldrin.*

| Cell origin                  | PHA response, cpm $\times 10^3$ |
|------------------------------|----------------------------------|
| Normal                       | 48                               |
| Normal + Mφ                  | 46                               |
| Leishmania (d. 20)           | 43                               |
| Leishmania + Mφ              | 49                               |
| Dieldrin (5 ppm, 10 wk)      | 43                               |
| Dieldrin + Mφ                | 18                               |
| Dieldrin/Leishmania          | 11                               |
| Dieldrin/Leishmania + Mφ     | 6                                |
| HCB (100 ppm, 10 wk) + Mφ    | 15                               |
| Half number of normal        | 25                               |

*Cells were prepared as described. Hepatic Kupffer, alveolar, splenic and peritoneal macrophage were isolated from dieldrin-treated Leishmania infected (d. 20) mice and cultured in RPMI 1640 + 10% FCS for 24 hr. Their supernatant was added to lymphocyte cultures simultaneously with the PHA; 50 μl of the supernatant was contained in each well.

factor which impaired T-cell responses to PHA was correlated with the ability of hepatic macrophage from dieldrin/Leishmania treated mice to process an antigen and to transfer an adequate immunogen to a recipient control animal. Similar alterations were observed with splenic macrophages but to a lesser degree (Table 9). The impaired antigen processing capability was correlated with dietary exposure time.

Discussion

Extensive interest in immunotoxicology has been generated within the past 5-6 years by the demonstration that various environmental chemical contaminants may, in laboratory situations, be immunosuppressive. However, apart from contact dermatitis, clinical evidence indicating environmental chemical-induced immune alteration has not been available; although several examples of autoimmune diseases generated by chemical exposure have been reported (12, 13).

Experimental immunotoxicologic data have primarily focused on evaluating the immunosuppressive effect of various environmental chemical

Table 9. Macrophage presentation of antigen in mice infected with malaria and Leishmania and receiving dieldrin or HBC.*

| Time, weeks | Chemical   | Macrophage donor type | PFC/10⁶ spleen cells |
|-------------|------------|------------------------|----------------------|
|             |            | Peritoneal             |                      |
|             |            | Splenic                |                      |
|             |            | Alveolar               |                      |
|             |            | Hepatic                |                      |
|             |            | Peritoneal             |                      |
|             |            | Splenic                |                      |
|             |            | Alveolar               |                      |
|             |            | Hepatic                |                      |
|             |            | Peritoneal             |                      |
|             |            | Splenic                |                      |
|             |            | Alveolar               |                      |
|             |            | Hepatic                |                      |
|             |            | Peritoneal             |                      |
|             |            | Splenic                |                      |
|             |            | Alveolar               |                      |
|             |            | Hepatic                |                      |
|             |            | Peritoneal             |                      |
|             |            | Splenic                |                      |
|             |            | Alveolar               |                      |
|             |            | Hepatic                |                      |
|             |            | Peritoneal             |                      |
|             |            | Splenic                |                      |
|             |            | Alveolar               |                      |
|             |            | Hepatic                |                      |
|             |            | Peritoneal             |                      |
|             |            | Splenic                |                      |
|             |            | Alveolar               |                      |
|             |            | Hepatic                |                      |
|             |            | Peritoneal             |                      |
|             |            | Splenic                |                      |
|             |            | Alveolar               |                      |
|             |            | Hepatic                |                      |
|             |            | Peritoneal             |                      |
|             |            | Splenic                |                      |
|             |            | Alveolar               |                      |
|             |            | Hepatic                |                      |
|             |            | Peritoneal             |                      |
|             |            | Splenic                |                      |
|             |            | Alveolar               |                      |
|             |            | Hepatic                |                      |
|             |            | Peritoneal             |                      |
|             |            | Splenic                |                      |
|             |            | Alveolar               |                      |
|             |            | Hepatic                |                      |
|             |            | Peritoneal             |                      |
|             |            | Splenic                |                      |
|             |            | Alveolar               |                      |
|             |            | Hepatic                |                      |
|             |            | Peritoneal             |                      |
|             |            | Splenic                |                      |
|             |            | Alveolar               |                      |
|             |            | Hepatic                |                      |
|             |            | Peritoneal             |                      |
|             |            | Splenic                |                      |
|             |            | Alveolar               |                      |
|             |            | Hepatic                |                      |
|             |            | Peritoneal             |                      |
|             |            | Splenic                |                      |
|             |            | Alveolar               |                      |
|             |            | Hepatic                |                      |
|             |            | Peritoneal             |                      |
|             |            | Splenic                |                      |
|             |            | Alveolar               |                      |
|             |            | Hepatic                |                      |
|             |            | Peritoneal             |                      |
|             |            | Splenic                |                      |
|             |            | Alveolar               |                      |
|             |            | Hepatic                |                      |
|             |            | Peritoneal             |                      |
|             |            | Splenic                |                      |
|             |            | Alveolar               |                      |
|             |            | Hepatic                |                      |
|             |            | Peritoneal             |                      |
|             |            | Splenic                |                      |
|             |            | Alveolar               |                      |
|             |            | Hepatic                |                      |
|             |            | Peritoneal             |                      |
|             |            | Splenic                |                      |
|             |            | Alveolar               |                      |
|             |            | Hepatic                |                      |

*Macrophages were isolated from dieldrin (5 ppm)- and HCB (100 ppm)-treated mice infected with malaria or Leishmania on days 4 and 20, respectively. SRBC were opsonized in 50% FCS for 30 min and labeled with Na¹¹⁶CrO₄. A standardized inoculum of ¹¹⁶Cr-SRBC was injected IV into control BALB/c mice and PFC/10⁶ cells were determined on day 4; n = 10.
contaminants, food additives, drugs and physical agents while, in general, disregarding the possible immunostimulation that may occur. In this regard, time and dose may be the critical determinants deciding whether a chemical contaminant is considered to be an immunostimulant or immunosuppressant. Furthermore, the catabolic capability of the lymphoid-macrophage elements at both a basal level and at an immune and/or stimulated level have been neglected.

Since the immune response of an organism is a complex multicellular and humoral event an evaluation of a chemical as an immunosuppressant should initially encompass an immune parameter which is a maximal determination of the host immune capacity. Such a measurement is best reflected in the assessment of the host defense using a challenge with a pathogen. The pathogen used may be a bacterium, virus or complex parasite. Indeed, a systematic evaluation of cell-mediated immunity and humoral immunity may be conducted using a series of various pathogens.

In addition to microbial pathogens, suitable parasitic models are also available. Commonly used parasites for immunological studies are: Schistosoma mansoni, Trichinella spiralis, Plasmodium berghei, Toxoplasma gondii, Trypanosoma cruzi, and Leishmania tropica. The present study utilized two of these parasites, Plasmodium berghei (NYU-2) and Leishmania tropica, to evaluate the influence of two common environmental chemical contaminants dieldrin and hexachlorobenzene (HCB) on host defense capacity and immune competence. Plasmodium berghei (NYU-2) is a lethal murine malaria which evokes a T-cell, B-cell and macrophage response. Although it is lethal, survival time is a reflection of immune competence. The L. tropica promastigote is a macrophage parasite which may or may not survive and proliferate in tissue macrophages depending on their functional status (14).

In the present study host defense mechanisms were more significantly impaired in dieldrin-treated mice than in mice receiving HCB. Indeed, the Leishmania model did appear to be a more sensitive indicator of immunotoxicity since mice bearing this parasite had a marked lethality whether treated with dieldrin or HCB (Table 1). However, immunosuppressive synergism to a T-dependent antigen, SRBC, in the parasite and chemical-treated mice was more evident in mice exposed to HCB than to dieldrin (Table 2). It appeared that the chemical and not the parasite was the determining factor in the antibody response to SRBC. However, when a T-independent antigen was used, i.e., PVP, the only statistically significant immunosuppressive synergism occurred in dieldrin and HCB-treated mice bearing the Leishmania parasite. Since the antibody response to PVP has been reported to be macrophage-independent (15) it would suggest that B-cells/plasma cells are the target cell type involved. Lack of an altered response to T-independent antigens in malaria infected mice has been reported. Since a significant decrease in splenic T-cells, B-cells and macrophages was only seen in the dieldrin/Leishmania treated mice in the 5 ppm-10 week group, a change in gross cellularity would seem not to be a causal factor. However, a functional alteration can obviously not be excluded.

In this regard, the marked synergism between Leishmania in both dieldrin- and HCB-treated mice in regard to their response to PHA denotes a very selective cellular impairment in T-cell functionality. Since the 5 ppm-10 wk dieldrin/Leishmania-treated group demonstrated the most consistent alteration in immune parameters, i.e., depressed SRBC response, depressed PVP responses, and decreased T, B and Mφ numbers and depressed PHA response, this group of animals was examined in greater detail for cellular hypofunctionality.

Treatment of splenic T-cell enriched populations from the dieldrin/Leishmania treated mice with mitomycin C to inhibit DNA synthesis or with antiserum to the Thy-1 antigen blocked their ability to inhibit the PHA response of normal T-cells. The inhibitory or suppressing activity suggested the presence of Thy-1 positive DNA synthesizing T-cells. Since induction of T-suppressor cells by macrophages has been demonstrated (16) the contribution of macrophages from dieldrin/Leishmania to the induction of T-suppressor cells (Ts) was investigated.

Isolated hepatic, and to a lesser extent splenic, macrophages produced a dialyzable factor that when added with PHA to splenic T-cell cultures, suppressed PHA stimulation of the T-cells. This macrophage T-cell suppressor factor did not influence normal control cells or T-cells from Leishmania infected mice. However, when added to T-cells from dieldrin/Leishmania mice or dieldrin or HCB-treated mice it inhibited their proliferative response. The inhibition seen in HCB derived T-cells suggests that the factor may act on organohalide-primed cells. Although activated macrophages have been demonstrated to secrete inhibitory factors (17) previous studies have shown that macrophages from organohalide xenobiotics are not activated (4). Indeed, as observed in Table 9, the inability of the macrophages to present an adequate immunogen to naive hosts indicates a suppressed state.

The demonstration that maximal suppressor factor was found associated with hepatic Kupffer cells may be, in part, related to hepatotoxicity of the two xenobiotics. If this is the case, it may provide a
valuable tool in the study of the relationship between hepatotoxicity and immunosuppression.

Further studies to elucidate the factor produced by the suppressor macrophages will evaluate interferon production as well as prostaglandins which have immunomodulatory roles (18). In addition, macrophage secreted factors may also compete with thymidine for its uptake into DNA by T-cells.

The incorporation of infectious disease models into immunotoxicologic studies may be a more relevant as well as more sensitive indicator of immunotoxicity. Although most studies have utilized mature animals, the use of neonates and aged animals in conjunction with stress may be a more accurate measurement of immune potential.

REFERENCES

1. Loose, L. D., Silkworth, J. B., Pittman, K. A., Benitz, K. F., and Mueller, W. Impaired host resistance to endotoxin and malaria in polychlorinated biphenyl- and hexachlorobenzene-treated mice. Infect. Immunol. 20: 30-35 (1978).

2. Loose, L. D., Pittman, K. A., Benitz, K. F., Silkworth, J. B., Mueller, W., and Coulston, F. Environmental chemical-induced immune dysfunction. Ecotox. Environ. Safety 2: 173-198 (1978).

3. Silkworth, J. B., and Loose, L. D. The assessment of environmental contaminant-induced lymphocyte dysfunction. Environ. Health Perspect. 39: 105-128 (1981).

4. Loose, L. D., Mueller, W., Charbonneau, T., and Blumenstock, F. Influence of xenobiotics on host defense. In: The Biological Relevance of Immune Suppression as Induced by Genetic, Therapeutic and Environmental Factors, J. Dean and M. Padarath Singh, Eds., Van Nostrand Reinhold, 1981, pp. 259-274.

5. Loose, L. D., Silkworth, J. B., Charbonneau, F., and Blumenstock, F. Environmental chemical-induced macrophage dysfunction. Environ. Health Perspect. 39: 79-91 (1981).

6. Jerne, N. K., and Nordin, A. A. Plaque formation in agar by single antibody-producing cells. Science 140: 405-406 (1963).

7. Boyden, S. V. The absorption of proteins on erythrocytes treated with tannic acid and subsequent hemagglutination by anti-protein sera. J. Exptl. Med. 93: 107-112 (1951).

8. LaViera, M. F., Loose, L. D., LaViera, D. S., and Silberman, M. S. The immunodepressive effect of phenol derivatives. Adv. Exptl. Biol. Med., Macrophages and Lymphocytes, Part A, M. Escobar and H. Friedman, Eds., Plenum Press, New York, 1980, pp. 523-538.

9. Yam, L. F., Li, C. Y., and Crosby, W. H. Cytochemical identification of monocytes and granulocytes. Am. J. Clin. Pathol. 55: 283-290 (1971).

10. Stege, T. E., Loose, L. D., and DiLuzio, N. R. Comparative uptake of sulfobromophthalein by isolated Kupffer and parenchymal cells. Proc. Soc. Exptl. Biol. Med. 149: 455-461 (1975).

11. Litchfield, J. T., Jr. A method for graphic solution of time-percent effect curves. J. Pharmacol. Exptl. Therap. 49: 399-408 (1949).

12. Hamilton, H. E., Morgan, D. P. and Simmons, A. A pesticide (dieldrin)-induced immunohemolytic anemia. Environ. Res. 17: 155-164 (1978).

13. Ward, M. Immunological mechanisms in the pathogenesis of vinyl chloride disease. Brit. Med. J. 1: 936-940 (1976).

14. Chang, K.-P. Leishmania infection of human skin fibroblasts in vitro: absence of phagolysosomal fusion after induced phagocytosis of promastigotes, and their intracellular transformation. Amer. J. Trop. Med. Hyg. 27: 1084-1096 (1978).

15. Wong, D. M., and Herscovitz, H. B. Immune activation by T-independent antigens: lack of effect of macrophage depletion on the immune response to TNP-LPS, PVP and dextran. Immunol. 37: 765-775 (1979).

16. Bash, J. A., and Cochran, F. R. Carrageenan-induced suppression of T lymphocyte proliferation in the rat: in vitro production of a suppressor factor by peritoneal macrophages. J. Reticuloendothel. Soc. 28: 203-211 (1980).

17. Nelson, D. S. Production by stimulated macrophages of factors depressing lymphocyte transformation. Nature 246: 306-308 (1973).

18. Gordon, D., Bray, M. A., and Morley, J. Control of lymphokine secretion by prostaglandins. Nature 262: 401-405 (1976).